Information Provided By:
Fly News Breaks for September 12, 2017
ICPT
Sep 12, 2017 | 11:35 EDT
Baird analyst Brian Skorney recommends buying Intercept shares on weakness related to the "Dear Healthcare Provider Letter." The analyst said there is no new information in the letter and serves as a reminder to modify does according to the label for patients with hepatic impairment following cases of Ocaliva being dosed more frequently than recommended. Skorny rates Intercept an Outperform with a $332 price target.
News For ICPT From the Last 2 Days
There are no results for your query ICPT